CompoAtlas

OriCell Re-Novo Capsule

OriCell Re-Novo Capsule : Product registered in Malaysia. This registration does not constitute authorisation for sale in France or the European Union. It does not demonstrate the safety or efficacy of the product.

NPRA, Malaysian pharmaceutical products register, retrieved 27 October 2026.

Ministry of Health Malaysia / NPRA, Pharmaceutical Products, CC BY 4.0

CC BY 4.0

The foreign register category does not determine the regulatory category of the product in France.

French and European references for recognised ingredients

No point flagged by the rules applied to recognised ingredients.

Unidentified ingredients are not assessed. The absence of a signal does not establish product compliance.

Published composition

Published ingredientPublished text and quantityIdentified nutrient or substance
Cordyceps sinensisCordyceps sinensis[150 mg,480 mg]Not identified
Arctostaphylos uva ursiArctostaphylos uva ursi[60 mg,480 mg]Not identified
Apium graveolensApium graveolens[30 mg,480 mg]Not identified
Vaccinium macrocarponVaccinium macrocarpon[50 mg,480 mg]Not identified
Phyllanthus niruriPhyllanthus niruri[30 mg,480 mg]Not identified
Vaccinium uliginosumVaccinium uliginosum[30 mg,480 mg]Not identified
Poria cocosPoria cocos[20 mg,480 mg]Not identified
Eucommia ulmoidesEucommia ulmoides[20 mg,480 mg]Not identified
Panax ginseng (Rubra)Panax ginseng (Rubra)[10 mg,480 mg]Not identified

The imported data provide no usable daily dosage. No daily dose is estimated and no comparison with dose limits is performed. A published quantity may refer to a preparation or an unspecified unit. Chinese names are retained without translation.

Product record

Registration number
MAL25086196T
Type
Natural product
Published status
PRODUCT APPROVED
Licence holder
EXCEL HERBAL INDUSTRIES SDN. BHD.
Manufacturer
EXCEL HERBAL INDUSTRIES SDN. BHD.
Registration period starting
2025-08-07
Published validity end
2030-08-07

Original register data

View published fields and their variants
Active ingredients
Cordyceps sinensis[150 mg,480 mg],Arctostaphylos uva ursi[60 mg,480 mg],Apium graveolens[30 mg,480 mg],Vaccinium macrocarpon[50 mg,480 mg],Phyllanthus niruri[30 mg,480 mg],Vaccinium uliginosum[30 mg,480 mg],Poria cocos[20 mg,480 mg],Eucommia ulmoides[20 mg,480 mg],Panax ginseng (Rubra)[10 mg,480 mg]
Valid until
2030-08-07
Registration date
2025-08-07
Published description
NATURAL PRODUCT
Licence holder
EXCEL HERBAL INDUSTRIES SDN. BHD.
Producer
EXCEL HERBAL INDUSTRIES SDN. BHD.
Published name
OriCell Re-Novo Capsule
Published reference
2025010617150T
Registration number
MAL25086196T
Published status
PRODUCT APPROVED

Official source

View the official register, number MAL25086196T

Ministry of Health Malaysia / NPRA, Pharmaceutical Products, CC BY 4.0

CC BY 4.0

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Vaccinium macrocarpon
    Read the warning, when it applies and the studies cited

    CRANBERRY - VACCINIUM MACROCARPON

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a history of kidney stones (Gettman et al. 2005; Terris et al. 2001).

    Sources cited by Health Canada (2)
    • Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CYC, Pearle MS. Effect of cranberry juice consumption on urinary stone risk factors. The Journal of Urology 2005;174(2):590-594. PubMed Randomised trial
    • Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57(1):26-29. PubMed

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Aston et al. 2006; Rindone and Murphy 2005; Grant 2004).

    Sources cited by Health Canada (4)
    • Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy 2006;26(9):1314-1319. PubMed
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Grant P. Warfarin and cranberry juice: an interaction? The Journal of Heart Valve Disease 2004;13(1):25-26. PubMed Case report
    • Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. American Journal of Therapeutics 2005;13(3):283-284.

    Condition of application: (Recurrent) urinary tract infection.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 27 March 2026

    DRIED CRANBERRY JUICE

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a history of kidney stones (Gettman et al. 2005; Terris et al. 2001).

    Sources cited by Health Canada (2)
    • Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CYC, Pearle MS. Effect of cranberry juice consumption on urinary stone risk factors. The Journal of Urology 2005;174(2):590-594. PubMed Randomised trial
    • Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57(1):26-29. PubMed

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Aston et al. 2006; Rindone and Murphy 2005; Grant 2004).

    Sources cited by Health Canada (4)
    • Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy 2006;26(9):1314-1319. PubMed
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Grant P. Warfarin and cranberry juice: an interaction? The Journal of Heart Valve Disease 2004;13(1):25-26. PubMed Case report
    • Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. American Journal of Therapeutics 2005;13(3):283-284.

    Condition of application: (Recurrent) urinary tract infection.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 27 March 2026

They concern the ingredient, not this product or its dose. They do not replace medical advice.

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “OriCell Re-Novo Capsule”, https://compoatlas.com/en/supplements/malaysia/MAL25086196T-oricell-re-novo-capsule, updated 27 October 2026.

Enter to analyse, Shift+Enter for a new line